SVB FINANCIAL GROUP
Q4 2022 Form 13-F
Filing Structure
Reports holdings for
- SVB Capital Management LLC · File #028-23867 · Q1 2024 – Q2 2024 · declared by one filing
- SVB Capital Management, LLC (not a 13F filer in our records) · Q4 2023 – Q4 2023 · declared by one filing
Key People
Directors & officers from Form 4 filingsDescription and Activity
SVB Financial Group, incorporated in Delaware in March 1999, is a diversified financial services and bank holding company primarily operating through its subsidiary, Silicon Valley Bank. The company provides banking and financial products to clients in the U.S. and international innovation markets, focusing on technology, life sciences/healthcare, private equity/venture capital, and premium wine industries. As of December 31, 2022, SVB Financial reported total assets of $211.8 billion, total loans of $74.3 billion, and total deposits of $173.1 billion.
The company's operations are divided into four segments: Silicon Valley Bank, SVB Private, SVB Capital, and SVB Securities. Silicon Valley Bank offers commercial banking services, including credit solutions, treasury management, foreign exchange, and trade finance products, particularly to clients in technology and healthcare sectors. SVB Private serves high-net-worth clients, mainly private equity and venture capital professionals, with private banking and wealth management services. SVB Capital manages funds for third-party investors, generating income through investment returns and management fees. SVB Securities functions as an investment bank, providing capital raising, M&A advisory, and equity research services, especially in healthcare and technology sectors.
SVB Financial generates revenue through net interest income (NII) and noninterest income. For the year ended December 31, 2022, NII was $4.5 billion, while noninterest income was $1.7 billion, primarily from fee-based services and investment banking activities. Most of its revenue comes from U.S. clients, with less than 10% from foreign clients. The client base includes emerging, mid-stage, and established companies in technology and life sciences, as well as private equity and venture capital firms, and premium wine producers in the western U.S. Key factors impacting the company's performance include competition from traditional banks, alternative lenders, Fintech companies, and investment banks.
Company description summarized from 10-K filing.Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2022 13F record
Q4 2022 13F filing summary
| Period of report | December 31, 2022 |
|---|---|
| Filed | February 14, 2023 |
| Form | 13F-HR |
| Reported value | $36.6M |
| Positions | 30 |
| Change in reported value | First reported quarter |
| Top-10 concentration | 92.5% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2024 13F
Filed Nov 12, 2024
|
1 | $434.2K |
|
Q2 2024 13F
Filed Aug 14, 2024
|
11 | $142.4M |
|
Q1 2024 13F
Filed May 14, 2024
|
13 | $181.4M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
13 | $112.8M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
21 | $53.2M |
|
Q2 2023 13F
Filed Aug 11, 2023
|
24 | $52.9M |
|
Q1 2023 13F
Filed May 15, 2023
|
28 | $52.3M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
30 | $36.6M |
Top 20 holdings · Q4 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | COIN COINBASE GLOBAL INC | $14.4M | 39.37% |
| 2 | OKTA OKTA INC | $7.7M | 20.92% |
| 3 | ROOT ROOT INC | $3.5M | 9.61% |
| 4 | AXSM AXSOME THERAPEUTICS INC | $2.6M | 7.14% |
| 5 | FROG JFROG LTD | $1.6M | 4.38% |
| 6 | DICE DICE THERAPEUTICS INC | $1.3M | 3.61% |
| 7 | CMAX CAREMAX INC | $1.1M | 2.99% |
| 8 | PL PLANET LABS PBC | $748.6K | 2.05% |
| 9 | OWLT OWLET INC | $492.8K | 1.35% |
| 10 | ROVR ROVER GROUP INC | $387.3K | 1.06% |
| 11 | NOGN NOGIN INC | $326.8K | 0.89% |
| 12 | CRBU CARIBOU BIOSCIENCES INC | $295.5K | 0.81% |
| 13 | CGEM CULLINAN ONCOLOGY INC | $285.2K | 0.78% |
| 14 | KROS KEROS THERAPEUTICS INC | $223.4K | 0.61% |
| 15 | ALVR ALLOVIR INC | $220.7K | 0.6% |
| 16 | GBIO GENERATION BIO CO | $208.0K | 0.57% |
| 17 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | $169.8K | 0.46% |
| 18 | KNTE KINNATE BIOPHARMA INC | $142.6K | 0.39% |
| 19 | SKLZXXXX SKILLZ INC | $138.7K | 0.38% |
| 20 | SLNA SELINA HOSPITALITY PLC | $136.1K | 0.37% |
Values as reported on the Q4 2022 Form 13F. Every position is in the holdings table below.